Navigation Links
Genoptix Reports Strong Financial Results For Third Quarter 2007
Date:12/12/2007

2007 2006

(unaudited)

Assets

Current assets:

Cash and cash equivalents $10,141 $3,865

Accounts receivable, net of allowance

for doubtful accounts 7,574 4,766

Prepaid expenses and other current assets 619 270

Total current assets 18,334 8,901

Property and equipment, net 1,670 1,287

Other long-term assets 1,262 14

Total assets $21,266 $10,202

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable and accrued expenses $4,109 $1,987

Accrued compensation 1,780 1,058

Deferred revenue 7 39

Current portion of long-term debt 1,458 1,524

Total current liabilities 7,354 4,608

Deferred rent, net of current portion 319 267

Long-term debt, net of current portion 409 1,262

Commitments and contingencies

Stockholders' equity:

Convertible preferred stock 52 52

Common stock - -

Additional paid-in capital 59,802 59,362

Accumulated deficit (46,670) (55,349)

Total stockholders' equity 13,184 4,065

Total liabilities and stockholders' equity $21,266 $10,202

GENOPTIX, INC.

CONDENSED CO
'/>"/>

SOURCE Genoptix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... ... take part in the first half of “Integrative Biotechnology,” an applied biotechnology course ... in summer 2014, this course combines students from both universities and is taught ...
(Date:6/30/2015)...  NASA astronaut Kjell Lindgren , who is making ... mission to the International Space Station , will be ... EDT Tuesday, July 7. Lindgren will participate from ... Russia . The interviews will be preceded at 7:30 ... training. To schedule an interview, media must contact ...
(Date:6/30/2015)... Francisco, CA (PRWEB) , ... June 30, 2015 ... ... FMT Patients , Study will provide new insights on mechanics of fecal microbiota ... a new partnership to study the microbiome of patients undergoing fecal microbiota transplantation ...
(Date:6/30/2015)... ... ... The maximum number of shares proposed to be purchased in the tender offer ... stock). On June 29, 2015, the last trading day prior to the commencement of ... was $2.29 per share. , The tender offer will expire on July 28, 2015 ...
Breaking Biology Technology:Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3
... SAN DIEGO, Jan. 7 Volcano Corporation,(Nasdaq: ... sales of,products for the diagnosis and treatment of coronary ... its previously announced acquisition of,Axsun Technologies, Inc. , ... manufacturer of lasers and optical,engines used in medical Optical ...
... Jan. 7 Sangart, Inc., a privately ... and,commercialization of oxygen-therapeutic agents, today announced a ... key leadership positions and,a significant reduction in ... This restructuring reduces the company,s burn rate ...
... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... Company will present,data from two ongoing Phase 2 clinical ... Oncology (ASCO) Symposia. , In ... Phase 2 trial,of picoplatin in patients with metastatic colorectal ...
Cached Biology Technology:Volcano Announces Closing of Axsun Technologies Acquisition 2Sangart, Inc. Announces Key Executive Appointments and Company Restructuring 2Sangart, Inc. Announces Key Executive Appointments and Company Restructuring 3Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers 2Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers 3
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.65 billion by ... 2014-2020 The near future will bring Biomedical ... each individual. These sensors can be set to trigger ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... 22, 2015 Research ... of the "Huawei Ascend Mate 7 Fingerprint ... their offering. Huawei,s technological choice for ... direction than Apple,s and Samsung,s one. The Ascend ... by Fingerprint Cards, a main actor in capacitive ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... RALEIGH, NC Methyl bromide (MeBr) is a highly ... control a wide variety of pests. Under the Montreal ... of the chemicals that contributed to the depletion of ... reduction in the amount of MeBr produced and imported ...
... Progress , Burnham Institute for Medical ... and license agreement with Johnson & Johnson ... this multi-year agreement, Burnham will provide J&JPRD ... to investigate certain drug targets for inflammatory ...
... Mass., Feb. 3, 2009 -- Despite the striking aromatic ... of the nose,s neural circuitry suggests a haphazard patchwork ... likely as not to be neighbors. Inexplicably, this ... even species, with cells that process the same scent ...
Cached Biology News:Methyl bromide alternatives indicated for North Carolina tomato production 2The Burnham Buzz, February 2009 2Neural mapping paints a haphazard picture of odor receptors 2
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
... MEGAscript RNAi Kit is optimized ... mass amounts of ready-to-use dsRNA ... systems. The MEGAscript RNAi Kit ... high-yield transcription technol-ogy and includes ...
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... Using its actuators as building blocks, ... work cell-level ,robotic solutions that are ... Beyond the base ,system, Parker can ... cups, custom structures, and ,guarding., ...
Biology Products: